Meeting
2023 ASCO Quality Care Symposium
Implementing a BRAF biomarker electronic clinical quality measure in CancerLinQ.
Authors
Caitlin Drumheller
American Society of Clinical Oncology, Alexandria, VA
Caitlin Drumheller, Afsaneh Barzi, Jacob Koskimaki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Quality Improvement Research and Implementation Science
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 418)
DOI
10.1200/OP.2023.19.11_suppl.418
Abstract #
418
Poster Bd #
H28
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
Poster
2022 ASCO Annual Meeting
The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).
First Author: Jenny F. Seligmann
Poster
2020 ASCO Quality Care Symposium
Impact of curated data on electronic quality measure capture rates within CancerLinQ.
First Author: Katrina Caridad Rios
Poster
2020 ASCO Virtual Scientific Program
Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.
First Author: Christos Stelios Karapetis